BioNeutral Group Signs Agreement With Hamilton Research to Market and Distribute Its Ygiene(R)-206 to the Veterinary Market
(firmenpresse) - NEWARK, NJ -- (Marketwire) -- 10/13/11 -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced that it has signed a distribution agreement with Hamilton Research LLC, an affiliate division of Hamilton Thorne Ltd. , to introduce, market and distribute its newly approved Ygiene®-206 Sterilant to the Veterinary industry.
Following many months of discussions and diligence between the scientific teams and management of both companies on the extraordinary properties of Ygiene's technology, it was decided to commence the process to formally introduce and distribute BioNeutral's Ygiene®-206 Sterilant to the Veterinary market.
BioNeutral's recently US/EPA approved, ready to use Ygiene-206 Sterilant has received acclaim in life science circles for its ability to kill ALL dangerous microorganisms with a dramatic increase in speed and power over its rivals in the marketplace. Ygiene's two in one full range multi-purpose cleaning properties combined with its non-toxic, non-corrosive killing power make this new game changing technology a devastating weapon against the spread of infections in all sectors of health and medical care. Ygiene-206 is completely environmentally safe containing NO chlorine bleach, heavy metals, aldehydes, quats, polluting phospates, phenolics, alkyl phenol ethoxlates or alcohol, thus making it the most effective infection control standard that can be applied.
Ms. Meg D. Hamilton (Spencer), Chairman of Hamilton Thorne Ltd. & CEO of Hamilton Research LLC, stated: "We at Hamilton Research are always vigilant to remain on the cutting edge of technology in all areas of our industry and business. Frankly, when I first heard about BioNeutral's Ygiene product I was skeptical to say the least, as it basically just sounded too good to be true. However, following our own scientific team's diligence on the product and its ultimate validation of being everything BioNeutral claimed it to be, I saw a real business opportunity." Ms. Hamilton went on to say, "The introduction of Ygiene-206 Sterilant into the Veterinary market will require a process of educating the end users as to Ygiene's multiple benefits versus the current predominantly bleach based products being used. Just its non-corrosive properties alone will save end users thousands of dollars in replacement costs for corroded instruments and equipment." She further stated, "We plan on introducing Ygiene-206 to the industry via a sequence of several Veterinary trade shows, direct advertising and on site demonstrations at Veterinary hospitals and DVM schools prior to year's end. I believe in working together with BioNeutral we will make these new innovative products a cornerstone in animal production and veterinary medicine."
"Having an impressive technology forward company such as Hamilton Research to first validate and then commit to introduce, market and distribute our Ygiene-206 Sterilant into the animal care market is a significant advancement for the company's long term growth strategy," stated Stephen J. Browand, President & CEO of BioNeutral Group, Inc., who went on to say, "Meg Hamilton and I have been in discussions since April of this year, and one thing is certain: the Hamilton Research team does their homework, and they will only represent products that are independently validated to be on the cutting edge of their presented technology platform." He further stated, "I am confident that given Hamilton's proactive marketing approach and stellar industry reputation as an innovator and leader make them the ideal company to launch Ygiene® into the Veterinarian market. This fact combined with their global distribution network, positions both companies for a long and mutually beneficial relationship."
Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge. Formed in 2001, Hamilton Thorne is a venture-backed company, headquartered in Beverly, Massachusetts. The Company employs an engineering, research, production and professional staff of thirty and has access to world-class scientists through its Scientific Advisory Board. For more information visit: . , an affiliate company, has recently been created to service the demands of the small animal veterinary medicine market as well as commercial animals such as cattle, sheep, pigs and chickens.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit .
Find us on Facebook:
Follow us on Twitter:
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2011 - 05:00 Uhr
Sprache: Deutsch
News-ID 1045461
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEWARK, NJ
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 124 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioNeutral Group Signs Agreement With Hamilton Research to Market and Distribute Its Ygiene(R)-206 to the Veterinary Market
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioNeutral Group, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
